Interstitial Cystitis Drugs Market Recorded 4.81% Y-O-Y Growth Rate in 2021| Evolving Opportunities with Perrigo Co. Plc & Pfizer Inc | Technavio

29 Jun 2022
www.prnewswire.com
NEW YORK, June 29, 2022 /PRNewswire/ -- The Interstitial Cystitis Drugs Market report provides a detailed analysis of the competitive scenario, the pre-and post-COVID-19 impact on businesses, and the market growth across various regions. The interstitial cystitis drugs market size is expected to increase by
USD 283.95 million, at a
CAGR of 5.06% from 2020 to 2025. Technavio categorizes the interstitial cystitis drugs market as a part of the
global pharmaceuticals market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the interstitial cystitis drugs market during the forecast period.
Interstitial Cystitis Drugs Market Recorded 4.81% Y-O-Y Growth Rate in 2021| Evolving Opportunities with Perrigo Co. Plc & Pfizer Inc | Technavio
Preview
Source: PRNewswire
Technavio has announced its latest market research report titled Interstitial Cystitis Drugs Market by Type and Geography - Forecast and Analysis 2021-2025
For more highlights on the parent market analysis - Request a sample now!
Market Dynamics
Drivers: The high prevalence of interstitial cystitis is notably driving the interstitial cystitis drugs market growth
Trends: Increasing awareness of interstitial cystitis is the key market trend driving the interstitial cystitis drugs market growth.
Challenges: The major challenge impeding the interstitial cystitis drugs market growth is the lack of approved drugs.
For detailed highlights on the market dynamics -
Segmentation Analysis
By Type, the market is classified into oral therapy and intravesical therapy.
The interstitial cystitis drugs market share growth by the
oral therapy segment will be significant for revenue generation. Pentosan polysulfate sodium (ELMIRON) is the only approved oral medication to repair the lining of the bladder in people with interstitial cystitis (IC). ELMIRON builds and restores the protective coating of the bladder tissue. There are many off-label oral drugs in the interstitial cystitis drugs market that can reduce the signs and symptoms of the disease facilitating the growth of the segment during the forecast period.
By Geography, the market is classified as North America, Europe, Asia, and ROW.
36% of the market's growth will originate from
North America during the forecast period. The US is a key market for interstitial cystitis drugs in North America. However, the market growth rate in this region will be slower than the growth of the market in Asia and Europe.
The increasing cases of interstitial cystitis and a rise in research funding will facilitate the interstitial cystitis drugs market growth in North America over the forecast period.
Company Profiles
The interstitial cystitis drugs market is
fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market. The interstitial cystitis drugs market report provides complete insights on key vendors including Astellas Pharma Inc., Bayer AG, Johnson and Johnson Inc., Novartis AG, Perrigo Co. Plc, Pfizer Inc., Seikagaku Corp., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Key Offerings:
Perrigo Co. Plc - The company offers pain and sleep aids such as Ibuprofen.
Pfizer Inc. - The company offers an interstitial cystitis drug named Toviaz.
Seikagaku Corp. - The company is developing the interstitial cystitis and bladder pain syndrome drug SI-722.
Sun Pharmaceutical Industries Ltd. - The company offers interstitial cystitis drugs such as Cystopen capsules
To know about all major vendor offerings - Grab a sample now!
Get ready to achieve excellent business outcomes from this exclusive Interstitial Cystitis Drugs Market report by Technavio. The report will include highlights of the overall market which includes frequently asked questions such as -
What are historical revenue figures and estimated revenue figures as well as CAGR during the forecast timeframe?
What is the current trend taking place in the market space?
Which are business tactics that will influence competitive scenarios along with defining the growth potential of the market?
What are market drivers, restraints, and challenges impacting demand & growth of the market?
Which regions & segments will garner massive revenue and emerge as market leaders in upcoming years?
The competitive scenario provided in the
Interstitial Cystitis Drugs Market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc. Don't wait, Make a strategic approach & boost your business goals with our Interstitial Cystitis Drugs Market Forecast Report -
Related Reports:
The
uveitis drugs market share is expected to increase to USD 269.65 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.9%.
The
vitiligo therapeutics market share is expected to increase to USD 341.35 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 4.5%.
Table of Content
1 Executive Summary
2 Market Landscape
2.1 Market ecosystem
Exhibit 01: Parent market
Exhibit 02: Market characteristics
2.2 Value chain analysis
Exhibit 03: Value chain analysis: Pharmaceuticals
3 Market Sizing
3.1 Market definition
Exhibit 04: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 05: Market segments
3.3 Market size 2020
3.4 Market outlook: Forecast for 2020 - 2025
Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million)
Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%)
4 Five Forces Analysis
4.1 Five forces summary
Exhibit 08: Five forces analysis 2020 & 2025
4.2 Bargaining power of buyers
Exhibit 09: Bargaining power of buyers
4.3 Bargaining power of suppliers
Exhibit 10: Bargaining power of suppliers
4.4 Threat of new entrants
Exhibit 11: Threat of new entrants
4.5 Threat of substitutes
Exhibit 12: Threat of substitutes
4.6 Threat of rivalry
Exhibit 13: Threat of rivalry
4.7 Market condition
Exhibit 14: Market condition - Five forces 2020
5 Market Segmentation by Type
5.1 Market segments
Exhibit 15: Type - Market share 2020-2025 (%)
5.2 Comparison by Type
Exhibit 16: Comparison by Type
5.3 Oral therapy - Market size and forecast 2020-2025
Exhibit 17: Oral therapy - Market size and forecast 2020-2025 ($ million)
Exhibit 18: Oral therapy - Year-over-year growth 2020-2025 (%)
5.4 Intravesical therapy - Market size and forecast 2020-2025
Exhibit 19: Intravesical therapy - Market size and forecast 2020-2025 ($ million)
Exhibit 20: Intravesical therapy - Year-over-year growth 2020-2025 (%)
5.5 Market opportunity by Type
Exhibit 21: Market opportunity by Type
6 Customer landscape
7 Geographic Landscape
7.1 Geographic segmentation
Exhibit 23: Market share by geography 2020-2025 (%)
7.2 Geographic comparison
Exhibit 24: Geographic comparison
7.3 North America - Market size and forecast 2020-2025
Exhibit 25: North America - Market size and forecast 2020-2025 ($ million)
Exhibit 26: North America - Year-over-year growth 2020-2025 (%)
7.4 Europe - Market size and forecast 2020-2025
Exhibit 27: Europe - Market size and forecast 2020-2025 ($ million)
Exhibit 28: Europe - Year-over-year growth 2020-2025 (%)
7.5 Asia - Market size and forecast 2020-2025
Exhibit 29: Asia - Market size and forecast 2020-2025 ($ million)
Exhibit 30: Asia - Year-over-year growth 2020-2025 (%)
7.6 ROW - Market size and forecast 2020-2025
Exhibit 31: ROW - Market size and forecast 2020-2025 ($ million)
Exhibit 32: ROW - Year-over-year growth 2020-2025 (%)
7.7 Key leading countries
Exhibit 33: Key leading countries
7.8 Market opportunity by geography
Exhibit 34: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
8.1 Market drivers
8.2 Market challenges
Exhibit 35: Impact of drivers and challenges
8.3 Market trends
9 Vendor Landscape
9.1 Overview
9.2 Vendor landscape
Exhibit 36: Vendor landscape
9.3 Landscape disruption
Exhibit 37: Landscape disruption
Exhibit 38: Industry risks
10 Vendor Analysis
10.1 Vendors covered
Exhibit 39: Vendors covered
10.2 Market positioning of vendors
Exhibit 40: Market positioning of vendors
Exhibit 41: Astellas Pharma Inc. - Overview
Exhibit 42: Astellas Pharma Inc. - Product and service
Exhibit 43: Astellas Pharma Inc. - Key news
Exhibit 44: Astellas Pharma Inc. - Key offerings
Exhibit 45: Bayer AG - Overview
Exhibit 46: Bayer AG - Business segments
Exhibit 47: Bayer AG - Key news
Exhibit 48: Bayer AG - Key offerings
Exhibit 49: Bayer AG - Segment focus
10.5 Johnson and Johnson Inc.
Exhibit 50: Johnson and Johnson Inc. - Overview
Exhibit 51: Johnson and Johnson Inc. - Business segments
Exhibit 52: Johnson and Johnson Inc. - Key news
Exhibit 53: Johnson and Johnson Inc. - Key offerings
Exhibit 54: Johnson and Johnson Inc. - Segment focus
Exhibit 55: Novartis AG - Overview
Exhibit 56: Novartis AG - Business segments
Exhibit 57: Novartis AG - Key news
Exhibit 58: Novartis AG - Key offerings
Exhibit 59: Novartis AG - Segment focus
Exhibit 60: Perrigo Co. Plc - Overview
Exhibit 61: Perrigo Co. Plc - Business segments
Exhibit 62: Perrigo Co. Plc - Key news
Exhibit 63: Perrigo Co. Plc - Key offerings
Exhibit 64: Perrigo Co. Plc - Segment focus
Exhibit 69: Seikagaku Corp. - Overview
Exhibit 70: Seikagaku Corp. - Business segments
Exhibit 71: Seikagaku Corp. - Key offerings
Exhibit 72: Seikagaku Corp. - Segment focus
Exhibit 73: Sun Pharmaceutical Industries Ltd. - Overview
Exhibit 74: Sun Pharmaceutical Industries Ltd. - Product and service
Exhibit 75: Sun Pharmaceutical Industries Ltd. - Key news
Exhibit 76: Sun Pharmaceutical Industries Ltd. - Key offerings
Exhibit 78: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 79: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 80: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 81: Viatris Inc. - Overview
Exhibit 82: Viatris Inc. - Business segments
Exhibit 83: Viatris Inc. - Key offerings
Exhibit 84: Viatris Inc. - Segment focus
11.1 Scope of the report
11.2 Currency conversion rates for US$
Exhibit 85: Currency conversion rates for US$
11.3 Research methodology
Exhibit 86: Research Methodology
Exhibit 87: Validation techniques employed for market sizing
Exhibit 88: Information sources
11.4 List of abbreviations
Exhibit 89: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.